1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: 
Patient data and prognostic factors in 145 noncensored patients with HGA
Prognostic Factor No. Survival (median) (95% CI)
Age^a 
    <50 years 21 330 (34–975)
    ≥50 years 124 178 (39–927)
Sex 
    Men 89 175 (41–924)
    Women 56 201 (40–954)
WHO grade^b 
    Anaplastic astrocytoma (III) 27 254 (43–963)
    Glioblastoma (IV) 118 178 (39–937)
Karnofsky Performance Status^a 
    <70 46 108 (39–472)
    70–80 56 197 (59–887)
    >80 43 278 (57–1238)
Extent of surgery^b 
    Biopsy 56 137 (28–849)
    Partial resection 53 197 (54–839)
    Complete resection 36 363 (63–1265)
Treatment^b 
    Conservative support 55 92 (28–249)
    Radiotherapy 27 222 (94–461)
    Chemoradiotherapy 63 330 (109–1154)


a No significant differences were found when only the noncensored patients were evaluated, but the differences reached significance level when the censored patients were included in the survival analysis.


b Significant differences were found with the logrank test.